MarginsXMarginsX
Home › Markets › Health Care › ARCT

Arcturus Therapeutics Holdings Inc. (ARCT)

ARCT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.31
-0.60% on the day
Market cap
$239.5M
Micro cap
Revenue · 2025
$82.0M
-46.1% on 2024
Net income · 2025
-$65.8M
-80.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/0001193125-26-088391-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerARCT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO year2013
SEC CIK0001768224
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$82.0M
Net income-$65.8M
Operating income-$76.3M
Net margin-80.2%
Operating margin-93.0%
Revenue growth-46.1%
Cash$230.9M
Total assets$271.1M
P/E (computed)Net income was not positive
P/S (computed)2.9×

Warning signs

Cash runway
35.5 months
$184.8M cash at September 30, 2026
Share count, 1 year
+1.4%
2025-11-05 to 2026-11-03 · +7.9% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$184.8M cash; operating cash flow -$15.6M a quarter.Report 2026-09-30
Shares outstanding28,822,514 (2026-11-03); 28,412,537 a year earlier; 26,723,332 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2025-12-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$18.3M-$7.4M-$6.9M$184.8MNo debt tags$30.5M10-Q 2026-11-05
Q2 2026
2026-06-30
$3.0M-$23.8M-$19.9M$191.5MNo debt tags$29.4M10-Q 2026-08-06
Q1 2026
2026-03-31
$2.1M-$27.0M-$19.4M$211.4MNo debt tags$54.7M10-Q 2026-05-07
Q4 2025
2025-12-31
$7.2M-$29.1M-$16.2M$230.9MNo debt tags$82.0M10-K 2026-03-03
Q3 2025
2025-09-30
$17.2M-$13.4M-$17.2M$180.4MNo debt tags$97.6M10-Q 2026-11-05
Q2 2025
2025-06-30
$28.3M-$9.2M-$5.8M$196.5MNo debt tags$122.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$29.4M-$14.1M-$35.1M$216.9M$15.0M$143.7M10-Q 2026-05-07
Q4 2024
2024-12-31
$22.8M-$30.0M-$284K$237.0MNo debt tags$152.3M10-K 2026-03-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-12-30
Latest annual report10-K2026-03-03
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-16
Latest proxyDEF 14A2026-04-24

Source: SEC EDGAR submissions feed, 418 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-19.2%
1 month-30.5%
3 months+6.4%
Year to date+36.4%
1 year+7.6%
From 52-week high-50.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M
CAMPCAMP4 Therapeutics Corporation$3.86+1.58%$242.2M
LFCRLifecore Biomedical Inc.$6.42-0.08%$243.2M
AMRNAmarin Corporation plc$11.31-0.62%$233.4M
QTTBQ32 Bio Inc.$8.29-4.82%$248.1M
VNDAVanda Pharmaceuticals Inc.$3.81-4.51%$230.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier